Indonesia’s National Health Insurance program, known as Jaminan Kesehatan Nasional (JKN), represents one of the largest and most ambitious healthcare reforms in the country’s history. Launched in 2014, JKN aims to provide universal health coverage (UHC) to over 270 million Indonesians, ensuring that all citizens have access to essential health services, including pharmaceuticals. This article explores the structure of the JKN program, its impact on the pharmaceutical sector, challenges, and future prospects. Visit pafikotamalili.org. Overview of the JKN Program JKN was introduced by the Indonesian government to address disparities in healthcare access and improve the overall health outcomes of the…
- 14/08/2024
- 8 min read
- 0